Oral/intravenous maintenance dosing of valproate following intravenous loading: a simulation

被引:20
作者
Dutta, S
Cloyd, JC
Granneman, GR
Collins, SD
机构
[1] Abbott Labs, Dept R4PK, Abbott Pk, IL 60064 USA
[2] Univ Minnesota, Coll Pharm, Minneapolis, MN 55455 USA
关键词
divalproex; plasma; pharmacokinetics; concentration; PHARMACOKINETICS; CHILDREN; ACID;
D O I
10.1016/S0920-1211(02)00252-8
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Valproic acid (VPA) has a narrow therapeutic range (50-100 mg/l) and exhibits nonlinear protein binding. Additionally, VPA pharmacokinetics are dependent on age, induction status, and formulation; so titration and dosing vary between individuals. The aim of these simulations was to determine optimal intravenous (i.v.) loading dose, and i.v. and oral VPA maintenance regimens. A 5-min 15 mg/kg loading dose resulted in total and free plasma VPA concentrations of similar to65 and 7.5 mg/l in children, and similar to80 and I I mg/l in adults, I h after the infusion; induction status had little effect. For uninduced children and adults, 7.5 and 3.5 mg/kg q6h i.v. valproate sodium, initiated 6 h after loading dose maintains therapeutic plasma VPA concentrations. The rapid decline of plasma VPA concentrations following an i.v. loading dose in combination with the delayed initial absorption of drug from delayed-release divalproex sodium tablets warrant beginning q12h oral maintenance regimens of delayed-release divalproex sodium within 2 h of a loading dose in the uninduced population. Plasma VPA concentrations can be sustained in the therapeutic range using once-daily maintenance regimens of extended-release divalproex. sodium tablets if initiated concurrently with i.v. loading dose in the uninduced population. A two-fold higher i.v. and oral maintenance regimen dose may be required in induced patients. (C) 2002 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:29 / 38
页数:10
相关论文
共 13 条
[1]   ABSORPTION CHARACTERISTICS OF A NEW VALPROATE FORMULATION - DIVALPROEX SODIUM-COATED PARTICLES IN CAPSULES (DEPAKOTE SPRINKLE) [J].
CARRIGAN, PJ ;
BRINKER, DR ;
CAVANAUGH, JH ;
LAMM, JE ;
CLOYD, JC .
JOURNAL OF CLINICAL PHARMACOLOGY, 1990, 30 (08) :743-747
[2]   COMPARISON OF STEADY-STATE PHARMACOKINETICS OF VALPROIC ACID IN CHILDREN BETWEEN MONOTHERAPY AND MULTIPLE ANTIEPILEPTIC DRUG-TREATMENT [J].
CHIBA, K ;
SUGANUMA, T ;
ISHIZAKI, T ;
IRIKI, T ;
SHIRAI, Y ;
NAITOH, H ;
HORI, M .
JOURNAL OF PEDIATRICS, 1985, 106 (04) :653-658
[3]   Valproate unbound fraction and distribution volume following rapid infusions in patients with epilepsy [J].
Cloyd, JC ;
Dutta, S ;
Cao, GL ;
Walch, JK ;
Collins, SD ;
Granneman, GR .
EPILEPSY RESEARCH, 2003, 53 (1-2) :19-27
[4]   VALPROIC ACID PHARMACOKINETICS IN CHILDREN .4. EFFECTS OF AGE AND ANTIEPILEPTIC DRUGS ON PROTEIN-BINDING AND INTRINSIC CLEARANCE [J].
CLOYD, JC ;
FISCHER, JH ;
KRIEL, RL ;
KRAUS, DM .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1993, 53 (01) :22-29
[5]   HOW OFTEN IS MEDICATION TAKEN AS PRESCRIBED - A NOVEL ASSESSMENT TECHNIQUE [J].
CRAMER, JA ;
MATTSON, RH ;
PREVEY, ML ;
SCHEYER, RD ;
OUELLETTE, VL .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1989, 261 (22) :3273-3277
[6]   PROGRAM PACKAGE FOR SIMULATION AND PARAMETER-ESTIMATION IN PHARMACOKINETIC SYSTEMS [J].
DARGENIO, DZ ;
SCHUMITZKY, A .
COMPUTER PROGRAMS IN BIOMEDICINE, 1979, 9 (02) :115-134
[7]  
*DEPACON PI VALPR, 2001, US PHYS DESK REF, P417
[8]  
*DEPAKOTE ER PI DI, 2001, US PHYS DESK REF, P3470
[9]  
*DEPAKOTE TABL PI, 2001, US PHYS DESK REF, P431
[10]   EFFECT OF FOOD ON THE SERUM CONCENTRATION PROFILE OF ENTERIC-COATED VALPROIC ACID [J].
FISCHER, JH ;
BARR, AN ;
PALOUCEK, FP ;
DOROCIAK, JV ;
SPUNT, AL .
NEUROLOGY, 1988, 38 (08) :1319-1322